MW Ozempic maker Novo Nordisk boots CEO over stock-price fall
By Steve Goldstein
Lars Fruergaard Jorgensen, the chief executive of once-highflying Danish drugmaker Novo Nordisk, is stepping down after eight years in the role, the maker of Ozempic and Wegovy drugs announced on Friday.
Novo Nordisk's stock (DK:NOVO.B) $(NVO)$ had soared in value, at one point becoming Europe's largest company by market capitalization, thanks to the wildly popular weight-loss medications, but now the stock has lost about half its value since peaking last summer.
Intense competition from Eli Lilly $(LLY)$ as well as so-called compounders, a disappointing study of a next-generation drug and trouble meeting supplies for its weight-loss drugs have all contributed to the company's struggles.
The changes are being made "in light of the recent market challenges Novo Nordisk has been facing, and the development of the company's share price since mid-2024," the company said.
In premarket trade, Novo Nordisk stock fell 3%.
The company said it's searching for a successor. In the meantime, the Novo Nordisk Foundation is having its chair participate as a board member.
-Steve Goldstein
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
May 16, 2025 07:37 ET (11:37 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。